Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Cellular Membranes and Drug Transport01:24

Cellular Membranes and Drug Transport

1.3K
Drugs must traverse multiple biological barriers, such as multi-layered skin, single-layered intestinal epithelium, and the plasma membrane, to reach their target sites within the body. The plasma membrane, a highly structured composite of phospholipids, carbohydrates, and proteins, is the cell's protective boundary, facilitating selective substance exchange.
Phospholipids arrange themselves into a bilayer, with hydrophilic heads oriented outward and hydrophobic tails facing inward.
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

System-Level Redesign of an Allogeneic Hematopoietic Cell Transplantation Program Associated with High 1-Year Survival and Reduced Cost.

Transplantation and cellular therapy·2026
Same author

Senescence-directed nanotherapy ameliorates fibrosis and overcomes immune exclusion in cancer.

bioRxiv : the preprint server for biology·2026
Same author

Tumor microenvironment-targeted PROTAC nanoparticle self-assembly broadly predicted by structural descriptors.

Science advances·2025
Same author

A Potent Inhibitor of Caspase‑8 Based on the IL-18 Tetrapeptide Sequence Reveals Shared Specificities between Inflammatory and Apoptotic Initiator Caspases.

ACS bio & med chem Au·2025
Same author

Trends of Authors' Conflicts of Interest in Clinical Trials Published in the <i>Journal of Clinical Oncology</i>: A Large Language Model-Assisted Longitudinal Study.

JCO oncology practice·2025
Same author

A human antibody specific for SIRPα reprograms macrophages and promotes antibody mediated anti-cancer activity.

PloS one·2025

Related Experiment Video

Updated: Dec 12, 2025

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

7.9K

Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery.

Thomas J Gardner1, Christopher M Bourne1,2, Megan M Dacek1,3

  • 1Molecular Pharmacology Program, Sloan Kettering Institute, New York, NY 10065, USA.

Cancers
|August 9, 2020
PubMed
Summary

Engineered T cells, like CAR T and TCR T cells, are emerging as powerful cancer therapies. These living drugs, or Targeted Cellular Micropharmacies, offer novel cell-mediated drug delivery for cancer treatment.

Keywords:
CAR TTCR therapyadoptive cell therapyarmored CARscell engineeringchimeric antigen receptor T cellgene therapyimmunotherapysynthetic biologysynthetic immunologytargeted cellular micropharmacy

More Related Videos

Cell Squeezing as a Robust, Microfluidic Intracellular Delivery Platform
08:02

Cell Squeezing as a Robust, Microfluidic Intracellular Delivery Platform

Published on: November 7, 2013

13.2K
Regioselective Biolistic Targeting in Organotypic Brain Slices Using a Modified Gene Gun
06:40

Regioselective Biolistic Targeting in Organotypic Brain Slices Using a Modified Gene Gun

Published on: October 24, 2014

16.9K

Related Experiment Videos

Last Updated: Dec 12, 2025

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

7.9K
Cell Squeezing as a Robust, Microfluidic Intracellular Delivery Platform
08:02

Cell Squeezing as a Robust, Microfluidic Intracellular Delivery Platform

Published on: November 7, 2013

13.2K
Regioselective Biolistic Targeting in Organotypic Brain Slices Using a Modified Gene Gun
06:40

Regioselective Biolistic Targeting in Organotypic Brain Slices Using a Modified Gene Gun

Published on: October 24, 2014

16.9K

Area of Science:

  • Oncology
  • Immunotherapy
  • Synthetic Biology

Background:

  • Engineered cellular therapies, including Chimeric Antigen Receptor (CAR) T cells and T Cell Receptor (TCR) engineered T cells, show significant promise for cancer treatment.
  • These engineered cells can accumulate and proliferate at tumor sites, enhancing immune responses and promoting tumor eradication.

Purpose of the Study:

  • To review recent advances and key considerations in the development of engineered cellular therapies.
  • To highlight the potential of these therapies as a new class of 'living drugs' for cancer treatment and beyond.

Main Methods:

  • Review of current literature on CAR T and TCR T cell therapies.
  • Discussion of advancements in synthetic biology and cell engineering for therapeutic applications.
  • Exploration of the concept of Targeted Cellular Micropharmacies (TCMs) as cell-mediated drug delivery systems.

Main Results:

  • Engineered T cells demonstrate potent anti-cancer activity through localized immune activation and tumor clearance.
  • The ability to engineer these cells with therapeutic payloads enables targeted modulation of the tumor microenvironment.
  • Cells are emerging as sophisticated vectors for drug delivery, establishing a new therapeutic paradigm.

Conclusions:

  • Targeted Cellular Micropharmacies (TCMs) represent a revolutionary approach to biological therapeutics.
  • These 'living drugs' hold significant potential to impact cancer medicine and other therapeutic areas.
  • Continued advancements in cell engineering are crucial for realizing the full potential of these novel therapies.